The National Heart, Lung, and Blood Institute (NHLBI) awarded a $635,396 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Dartmouth-Hitchcock Clinic, doing business as Dartmouth-Hitchcock Obligated Group, to investigate the mechanisms underlying impaired inflammation resolution in cystic fibrosis (CF) lung disease. The research aims to characterize differences in lung macrophage subpopulations, metabolic profiles, and extracellular vesicle signaling between CF patients, non-CF bronchiectasis patients, and healthy controls. Dartmouth-Hitchcock Clinic has subcontracted a portion of the work to Trustees of Dartmouth College, who will provide research services, advisory support, and regulatory oversight as part of the grant activities. The award period runs from Aug 1, 2024 to Apr 30, 2028 and seeks to identify novel targets for therapies to reduce harmful lung inflammation and improve outcomes for people living with CF.
Generated 1/28/25, 8:12 AM